Dimitry Ofengeim

7.9k total citations · 4 hit papers
36 papers, 4.5k citations indexed

About

Dimitry Ofengeim is a scholar working on Molecular Biology, Immunology and Cellular and Molecular Neuroscience. According to data from OpenAlex, Dimitry Ofengeim has authored 36 papers receiving a total of 4.5k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Molecular Biology, 11 papers in Immunology and 8 papers in Cellular and Molecular Neuroscience. Recurrent topics in Dimitry Ofengeim's work include Cell death mechanisms and regulation (9 papers), Neuroinflammation and Neurodegeneration Mechanisms (8 papers) and interferon and immune responses (6 papers). Dimitry Ofengeim is often cited by papers focused on Cell death mechanisms and regulation (9 papers), Neuroinflammation and Neurodegeneration Mechanisms (8 papers) and interferon and immune responses (6 papers). Dimitry Ofengeim collaborates with scholars based in United States, France and China. Dimitry Ofengeim's co-authors include Junying Yuan, Palak Amin, Lauren Mifflin, Alexei Degterev, Chengyu Zou, Hongbo Chen, R. Suzanne Zukin, Judy Park DeWitt, Hong Zhu and Xian Adiconis and has published in prestigious journals such as Cell, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Dimitry Ofengeim

35 papers receiving 4.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Necroptosis and RIPK1-mediated neuroinflammation in CNS diseases

2018 685 citations Junying Yuan, Palak Amin et al. Nature reviews. Neuroscience profile →
A guide to cell death pathways

2023 443 citations Junying Yuan, Dimitry Ofengeim Nature Reviews Molecular Cell Biology profile →
Activation of Necroptosis in Multiple Sclerosis

2015 419 citations Dimitry Ofengeim, Yasushi Ito et al. profile →
Receptor-interacting protein kinase 1 (RIPK1) as a therapeutic target

2020 310 citations Lauren Mifflin, Dimitry Ofengeim et al. Nature Reviews Drug Discovery profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Dimitry Ofengeim United States	22	2.9k	1.3k	721	634	591	36	4.5k
Hongmin Wang China	27	3.4k 1.2×	644 0.5×	675 0.9×	317 0.5×	361 0.6×	111	5.1k
Sun Sik Bae South Korea	37	2.8k 0.9×	600 0.5×	454 0.6×	212 0.3×	499 0.8×	120	4.5k
Junichi Hitomi Japan	15	3.1k 1.1×	1.1k 0.8×	1.1k 1.5×	143 0.2×	450 0.8×	17	4.6k
Deborah A. Ferrington United States	41	4.1k 1.4×	573 0.4×	654 0.9×	359 0.6×	244 0.4×	115	6.0k
Cathy Tournier United Kingdom	36	4.4k 1.5×	1.0k 0.8×	436 0.6×	188 0.3×	911 1.5×	59	6.1k
Michael Maceyka United States	40	8.0k 2.7×	1.3k 1.0×	726 1.0×	365 0.6×	400 0.7×	55	9.1k
Dong‐Hyung Cho South Korea	37	3.2k 1.1×	334 0.3×	1.2k 1.7×	206 0.3×	609 1.0×	133	5.0k
Alessandro Alessandrini United States	32	2.7k 0.9×	759 0.6×	200 0.3×	319 0.5×	310 0.5×	56	4.6k
Stephan Kemp Netherlands	38	6.3k 2.2×	584 0.4×	368 0.5×	332 0.5×	514 0.9×	110	7.5k
Andrea Huwiler Germany	47	4.8k 1.6×	871 0.7×	308 0.4×	316 0.5×	522 0.9×	156	6.5k

Countries citing papers authored by Dimitry Ofengeim

Since Specialization

Citations

This map shows the geographic impact of Dimitry Ofengeim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dimitry Ofengeim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dimitry Ofengeim more than expected).

Fields of papers citing papers by Dimitry Ofengeim

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dimitry Ofengeim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dimitry Ofengeim. The network helps show where Dimitry Ofengeim may publish in the future.

Co-authorship network of co-authors of Dimitry Ofengeim

This figure shows the co-authorship network connecting the top 25 collaborators of Dimitry Ofengeim. A scholar is included among the top collaborators of Dimitry Ofengeim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dimitry Ofengeim. Dimitry Ofengeim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gruber, Ross C., Michael R. Dufault, Nellwyn Hagan, et al.. (2024). BTK regulates microglial function and neuroinflammation in human stem cell models and mouse models of multiple sclerosis. Nature Communications. 15(1). 10116–10116. 11 indexed citations

Hincelin-Méry, Agnès, Cathy Cantalloube, Robert J. Pomponio, et al.. (2023). Safety, pharmacokinetics, and target engagement of a brain penetrant RIPK1 inhibitor, SAR443820 (DNL788), in healthy adult participants. Clinical and Translational Science. 17(1). e13690–e13690. 21 indexed citations

Hincelin-Méry, Agnès, Cathy Cantalloube, Myriam Bénamor, et al.. (2023). First-in-Human Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAR443820, a Central Nervous System Penetrant RIPK1 Inhibitor in Healthy Participants (S46.005). Neurology. 100(17_supplement_2). 1 indexed citations

Gruber, Ross C., et al.. (2022). Evaluating the Effect of BTK Inhibitor Tolebrutinib in Human Tri-culture (P1-1.Virtual). Neurology. 98(18_supplement). 5 indexed citations

Hagan, Nellwyn, John L. Kane, Deepak Grover, et al.. (2020). CSF1R signaling is a regulator of pathogenesis in progressive MS. Cell Death and Disease. 11(10). 904–904. 95 indexed citations

Gruber, Ross C., Nathalie Chrétien, Michael R. Dufault, et al.. (2020). Central Effects of BTK Inhibition in Neuroinflammation (808). Neurology. 94(15_supplement). 10 indexed citations

Mifflin, Lauren, Dimitry Ofengeim, & Junying Yuan. (2020). Receptor-interacting protein kinase 1 (RIPK1) as a therapeutic target. Nature Reviews Drug Discovery. 19(8). 553–571. 310 indexed citations breakdown →

Amin, Palak, Marcus A. Florez, Ayaz Najafov, et al.. (2018). Regulation of a distinct activated RIPK1 intermediate bridging complex I and complex II in TNFα-mediated apoptosis. Proceedings of the National Academy of Sciences. 115(26). E5944–E5953. 120 indexed citations

Chen, Hongbo, et al.. (2018). Exploring the genetics and non-cell autonomous mechanisms underlying ALS/FTLD. Cell Death and Differentiation. 25(4). 648–662. 64 indexed citations

10.

Su, Zhenyi, Die Hu, Nicole M. Broekema, et al.. (2018). ABIN-1 heterozygosity sensitizes to innate immune response in both RIPK1-dependent and RIPK1-independent manner. Cell Death and Differentiation. 26(6). 1077–1088. 17 indexed citations

11.

Yuan, Junying, Palak Amin, & Dimitry Ofengeim. (2018). Necroptosis and RIPK1-mediated neuroinflammation in CNS diseases. Nature reviews. Neuroscience. 20(1). 19–33. 685 indexed citations breakdown →

12.

Ofengeim, Dimitry, Νικόλαος Γιαγτζόγλου, Dann Huh, Chengyu Zou, & Junying Yuan. (2017). Single-Cell RNA Sequencing: Unraveling the Brain One Cell at a Time. Trends in Molecular Medicine. 23(6). 563–576. 104 indexed citations

13.

Hwang, Jee-Yeon, Michael Gertner, Fabrizio Pontarelli, et al.. (2016). Global ischemia induces lysosomal-mediated degradation of mTOR and activation of autophagy in hippocampal neurons destined to die. Cell Death and Differentiation. 24(2). 317–329. 88 indexed citations

14.

Afonso, Marta B., Pedro M. Rodrigues, André L. Simão, et al.. (2016). Activation of necroptosis in human and experimental cholestasis. Cell Death and Disease. 7(9). e2390–e2390. 104 indexed citations

15.

Vakifahmetoglu-Norberg, Helin, Minsu Kim, Hongguang Xia, et al.. (2013). Chaperone-mediated autophagy degrades mutant p53. Genes & Development. 27(15). 1718–1730. 168 indexed citations

16.

Ofengeim, Dimitry & Junying Yuan. (2013). Regulation of RIP1 kinase signalling at the crossroads of inflammation and cell death. Nature Reviews Molecular Cell Biology. 14(11). 727–736. 477 indexed citations

17.

Ofengeim, Dimitry, Ying‐Bei Chen, Takahiro Miyawaki, et al.. (2012). N-terminally cleaved Bcl-xL mediates ischemia-induced neuronal death. Nature Neuroscience. 15(4). 574–580. 60 indexed citations

18.

Ofengeim, Dimitry, Peng Shi, Benchun Miao, et al.. (2012). Identification of Small Molecule Inhibitors of Neurite Loss Induced by Aβ peptide using High Content Screening. Journal of Biological Chemistry. 287(12). 8714–8723. 20 indexed citations

19.

Miyawaki, Takahiro, Dimitry Ofengeim, Kyung‐Min Noh, et al.. (2009). The endogenous inhibitor of Akt, CTMP, is critical to ischemia-induced neuronal death. Nature Neuroscience. 12(5). 618–626. 94 indexed citations

20.

Miyawaki, Takahiro, Toshihiro Mashiko, Dimitry Ofengeim, et al.. (2008). Ischemic preconditioning blocks BAD translocation, Bcl-x _L cleavage, and large channel activity in mitochondria of postischemic hippocampal neurons. Proceedings of the National Academy of Sciences. 105(12). 4892–4897. 71 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact